## ACNB: ACNB Corporation - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-6.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($47.93)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 14 ($0.14M) |
| Sells | 2 ($0.40M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 30.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- FMR, LLC: 5.8% (0.0%)
- Blackrock Inc.: 5.8% (-1.4%)
- Vanguard Group Inc: 5.1% (-1.9%)
- Private Capital Mana: 3.3% (+9.9%)
- Dimensional Fund Adv: 3.0% (+2.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 10.0x stretched relative to 2% growth. Quality metrics strong (margin 24%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.5B |
| Beta | 0.86 |
| 52W Range | $35.70 - $53.41 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 10.0 |
| Current P/E | 10.2 |
| YoY Growth | 2.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.8% to -0.1% (-6.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.08% (CS: 46) | Neutral |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.150x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $50.51
- **Stop Loss:** $47.93 (5.1% risk)
- **Target:** $55.67 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 348
- **Position Value:** $17,577.48
- **Portfolio %:** 17.58%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-22 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.18 | $1.44 | +21.7% |
| 2025Q2 | $1.15 | $1.25 | +8.8% |
| 2025Q1 | $0.93 | $0.79 | -15.0% |
| 2024Q4 | $0.85 | $0.86 | +0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*